PL3049100T3 - Zmodyfikowane czynniki wzrostu fibroblastu-1 do leczenia zaburzeń ocznych - Google Patents
Zmodyfikowane czynniki wzrostu fibroblastu-1 do leczenia zaburzeń ocznychInfo
- Publication number
- PL3049100T3 PL3049100T3 PL14849458T PL14849458T PL3049100T3 PL 3049100 T3 PL3049100 T3 PL 3049100T3 PL 14849458 T PL14849458 T PL 14849458T PL 14849458 T PL14849458 T PL 14849458T PL 3049100 T3 PL3049100 T3 PL 3049100T3
- Authority
- PL
- Poland
- Prior art keywords
- treatment
- growth factors
- fibroblast growth
- ocular disorders
- modified fibroblast
- Prior art date
Links
- 208000022873 Ocular disease Diseases 0.000 title 1
- 210000002950 fibroblast Anatomy 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
- A61K38/1825—Fibroblast growth factor [FGF]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0048—Eye, e.g. artificial tears
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/475—Growth factors; Growth regulators
- C07K14/50—Fibroblast growth factor [FGF]
- C07K14/501—Fibroblast growth factor [FGF] acidic FGF [aFGF]
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Zoology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Ophthalmology & Optometry (AREA)
- Molecular Biology (AREA)
- Toxicology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Dermatology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Materials For Medical Uses (AREA)
- Prostheses (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361882561P | 2013-09-25 | 2013-09-25 | |
| EP14849458.6A EP3049100B1 (en) | 2013-09-25 | 2014-09-24 | Modified fibroblast growth factors-1 for the treatment of ocular disorders |
| PCT/US2014/057302 WO2015048188A2 (en) | 2013-09-25 | 2014-09-24 | Modified fibroblast growth factors for the treatment of ocular disorders |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PL3049100T3 true PL3049100T3 (pl) | 2020-06-01 |
Family
ID=52744699
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL14849458T PL3049100T3 (pl) | 2013-09-25 | 2014-09-24 | Zmodyfikowane czynniki wzrostu fibroblastu-1 do leczenia zaburzeń ocznych |
Country Status (9)
| Country | Link |
|---|---|
| US (2) | US11103553B2 (pl) |
| EP (3) | EP4420722A3 (pl) |
| DK (1) | DK3049100T3 (pl) |
| ES (2) | ES2986728T3 (pl) |
| HR (1) | HRP20200257T1 (pl) |
| HU (1) | HUE051295T2 (pl) |
| PL (1) | PL3049100T3 (pl) |
| SI (1) | SI3049100T1 (pl) |
| WO (1) | WO2015048188A2 (pl) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HUE051295T2 (hu) | 2013-09-25 | 2021-03-01 | Trefoil Therapeutics Llc | Módosított fibroblaszt növekedési faktorok-1 szembetegségek kezelésére |
| EP3436608A4 (en) * | 2016-03-28 | 2019-12-04 | Trefoil Therapeutics, Inc. | MODIFIED FIBROBLAST GROWTH FACTORS AND USES THEREOF |
| EP4621067A3 (en) | 2017-05-05 | 2025-11-19 | Trefoil Therapeutics, Inc. | Recombinant modified fibroblast growth factors and therapeutic uses thereof |
| TWI674124B (zh) * | 2017-09-30 | 2019-10-11 | 三凡生技研發股份有限公司 | 促進眼睛保健之胜肽及其組合物 |
| CN113289005B (zh) * | 2021-07-06 | 2022-05-31 | 温州医科大学 | rhFGF-21在制备治疗干眼症药物中的应用 |
| WO2023019218A1 (en) * | 2021-08-12 | 2023-02-16 | Trefoil Therapeutics, Inc. | Modified fibroblast growth factors for treating fibrotic diseases |
| CN115177717A (zh) * | 2022-08-31 | 2022-10-14 | 贵州医科大学附属医院 | 一种治疗眼表及角膜上皮疾病的药物 |
Family Cites Families (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5223483A (en) | 1987-10-22 | 1993-06-29 | Merck & Co., Inc. | Cysteine-modified acidic fibroblast growth factor |
| US5312911A (en) | 1987-10-22 | 1994-05-17 | Merck & Co., Inc. | Cysteine-modified acidic fibroblast growth factor |
| US5033252A (en) | 1987-12-23 | 1991-07-23 | Entravision, Inc. | Method of packaging and sterilizing a pharmaceutical product |
| US5052558A (en) | 1987-12-23 | 1991-10-01 | Entravision, Inc. | Packaged pharmaceutical product |
| US5510329A (en) * | 1988-04-26 | 1996-04-23 | Ramot University For Applied Research And Industrial Development Ltd. | Preparations for the treatment of eyes |
| US6780837B1 (en) * | 1989-08-30 | 2004-08-24 | The Regents Of The University Of California | Prevention of retinal injury and degeneration by specific factors |
| US5124154A (en) * | 1990-06-12 | 1992-06-23 | Insite Vision Incorporated | Aminosteroids for ophthalmic use |
| US5323907A (en) | 1992-06-23 | 1994-06-28 | Multi-Comp, Inc. | Child resistant package assembly for dispensing pharmaceutical medications |
| US5624893A (en) * | 1993-10-14 | 1997-04-29 | Alcon Laboratories, Inc. | Pharmaceutical compositions and methods of treatment of the cornea following laser irradiation |
| GB9523946D0 (en) | 1995-11-23 | 1996-01-24 | Bayer Ag | Leukotriene antagonistic benzoic acid derivatives |
| AU3170499A (en) * | 1998-04-28 | 1999-11-16 | Eisai Co. Ltd. | Fibroblast growth factor mutein compositions and methods of use therefor |
| US20050227929A1 (en) | 2003-11-13 | 2005-10-13 | Masferrer Jaime L | Combination therapy comprising a Cox-2 inhibitor and an antineoplastic agent |
| US7790682B1 (en) | 2003-12-02 | 2010-09-07 | The Florida State University Research Foundation, Inc. | Engineered human acidic fibroblast growth factors and associated methods |
| US8541413B2 (en) * | 2004-10-01 | 2013-09-24 | Ramscor, Inc. | Sustained release eye drop formulations |
| WO2006105315A2 (en) * | 2005-03-29 | 2006-10-05 | Massachusetts Institute Of Technology | Compositions and methods for regulating inflammatory responses |
| US7776825B1 (en) * | 2006-11-09 | 2010-08-17 | Florida State University Research Foundation, Incorporated | Mutant polypeptides of fibroblast growth factor 1 |
| US7659379B1 (en) * | 2007-05-24 | 2010-02-09 | Florida State University Research Foundation, Inc. | Mutants of human fibroblast growth factor having increased stability and/or mitogenic potency |
| US8461111B2 (en) | 2009-05-20 | 2013-06-11 | Florida State University Research Foundation | Fibroblast growth factor mutants having improved functional half-life and methods of their use |
| US20110224404A1 (en) | 2010-03-11 | 2011-09-15 | Florida State University Research Foundation | Method for development of a peptide building block useful for de novo protein design |
| HUE051295T2 (hu) | 2013-09-25 | 2021-03-01 | Trefoil Therapeutics Llc | Módosított fibroblaszt növekedési faktorok-1 szembetegségek kezelésére |
| WO2015198175A1 (en) * | 2014-06-27 | 2015-12-30 | Florida State University Research Foundation, Inc. | Design of fgf-1 mutants to effectively eliminate reactive cysteine residues |
-
2014
- 2014-09-24 HU HUE14849458A patent/HUE051295T2/hu unknown
- 2014-09-24 EP EP24182441.6A patent/EP4420722A3/en active Pending
- 2014-09-24 EP EP14849458.6A patent/EP3049100B1/en active Active
- 2014-09-24 ES ES19209445T patent/ES2986728T3/es active Active
- 2014-09-24 ES ES14849458T patent/ES2773574T3/es active Active
- 2014-09-24 DK DK14849458.6T patent/DK3049100T3/da active
- 2014-09-24 US US15/024,824 patent/US11103553B2/en active Active
- 2014-09-24 WO PCT/US2014/057302 patent/WO2015048188A2/en not_active Ceased
- 2014-09-24 HR HRP20200257TT patent/HRP20200257T1/hr unknown
- 2014-09-24 EP EP19209445.6A patent/EP3666791B1/en active Active
- 2014-09-24 PL PL14849458T patent/PL3049100T3/pl unknown
- 2014-09-24 SI SI201431500T patent/SI3049100T1/sl unknown
-
2021
- 2021-07-16 US US17/378,557 patent/US20210338777A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| DK3049100T3 (da) | 2020-03-02 |
| EP3049100A2 (en) | 2016-08-03 |
| EP4420722A2 (en) | 2024-08-28 |
| EP3049100A4 (en) | 2017-06-07 |
| US20210338777A1 (en) | 2021-11-04 |
| EP3666791B1 (en) | 2024-06-19 |
| WO2015048188A3 (en) | 2015-06-04 |
| HUE051295T2 (hu) | 2021-03-01 |
| US11103553B2 (en) | 2021-08-31 |
| US20160263190A1 (en) | 2016-09-15 |
| EP3666791A1 (en) | 2020-06-17 |
| ES2773574T3 (es) | 2020-07-13 |
| EP4420722A3 (en) | 2024-11-27 |
| WO2015048188A8 (en) | 2016-03-17 |
| ES2986728T3 (es) | 2024-11-12 |
| HRP20200257T1 (hr) | 2020-09-04 |
| EP3049100B1 (en) | 2019-11-20 |
| WO2015048188A2 (en) | 2015-04-02 |
| SI3049100T1 (sl) | 2020-04-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL288712A (en) | Methods for treating abnormal movement disorders | |
| IL274771A (en) | Use of pyrazolopyrimidine derivatives for the treatment of PI3Kδ associated disorders | |
| PL3811943T3 (pl) | Związek do stosowania w leczeniu zaburzeń oczu | |
| PL2968218T3 (pl) | Skojarzenie do leczenia choroby parkinsona | |
| IL243976A0 (en) | kdm1a inhibitors for disease treatment | |
| IL243485A0 (en) | Methods for treating or preventing ophthalmological conditions | |
| IL240931A0 (en) | History 3 - Phenylpropylamine is converted to the treatment of eye diseases and disorders | |
| SI3049100T1 (sl) | Modificirani faktorji rasti fibroblasta-1 za zdravljenje očesnih motenj | |
| EP3060259A4 (en) | Methods of treating or preventing vascular diseases of the retina | |
| HUE039750T2 (hu) | Hidroxi-buspiron mozgászavarok kezelésére | |
| GB2541840B (en) | Ophthalmic composition for the treatment of ocular infection | |
| ZA201507718B (en) | The local treatment of inflammatory ophthalmic diseases | |
| SG10201802808SA (en) | Method of treating ocular disorders | |
| GB201306413D0 (en) | The local treatment of ophthalmic diseases | |
| EP2970118A4 (en) | COMPOUNDS FOR THE TREATMENT OF NEUROLOGICAL DISORDERS | |
| GB201308302D0 (en) | Cream for treatment of the skin | |
| GB201303721D0 (en) | Compositions for treatment of sleep disorders |